Staffan Encrantz bought $382k of SGHT
director, owner at Sight Sciences, Inc.. 90,525 shares at an average of $4.22, traded Jun 4, 2025, filed Jun 6, 2025.
Score components
- +15RoleDirector
- +16Trade size$382k at market
- +3Relative to holdingsHoldings up 7%
- +8Price context39% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying3 buys in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-083413, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 4, 2025 | POpen-market purchase Common Stock | +21,674 | $4.17 | $90k | 1,278,161 | Jun 6, 2025 |
| Jun 5, 2025 | POpen-market purchase Common Stock | +40,951 | $4.24 | $174k | 1,319,112 | Jun 6, 2025 |
| Jun 5, 2025 | AGrant or award Common Stock | +30,952 | $0.00 | $0 | 1,350,064 | Jun 6, 2025 |
| Jun 6, 2025 | POpen-market purchase Common Stock | +27,900 | $4.22 | $118k | 1,377,964 | Jun 6, 2025 |
Related signals
Other insiders at Sight Sciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 18Weak | Sight Sciences, Inc. | David Badawi Chief Technology Officer | $71k 7,797 shares | -0% | |
| 33Weak | Sight Sciences, Inc. | Paul Badawi President and CEO | $268k 29,653 shares | -0% | |
| 27Weak | Sight Sciences, Inc. | Alison Bauerlein Chief Operating Officer | $224k 25,260 shares | -4% | |
| 25Weak | Sight Sciences, Inc. | James Rodberg Chief Financial Officer | $64k 7,208 shares | -3% | |
| 15Weak | Sight Sciences, Inc. | Brenton Taylor EVP, Operations & R&D | $26k 2,988 shares | -1% | |
| 26Weak | SGHTbuy Sight Sciences, Inc. | Staffan Encrantz director, owner | $69k 14,100 shares | +1% | |
| 8Weak | Sight Sciences, Inc. | Alison Bauerlein Chief Operating Officer | $65k 12,728 shares | -2% | |
| 15Weak | Sight Sciences, Inc. | David Badawi Chief Technology Officer | $28k 8,168 shares | -0% | |
| 30Weak | Sight Sciences, Inc. | Paul Badawi President and CEO | $108k 29,244 shares | -0% | |
| 24Weak | Sight Sciences, Inc. | Alison Bauerlein Chief Operating Officer | $90k 25,874 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.